GlassScriptPhysician profile
Kenneth T Horlander
NPI 1093750051
$13,144.05
in general payments reported to CMS, 2019-2025
23 companies · $6,771 in 2025
The $6,771 reported for 2025 was more than what 90% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $522 · 2021: $837 · 2022: $2,682 · 2023: $1,355 · 2024: $754 · 2025: $6,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,117 · Food and Beverage: $2,674 · Travel and Lodging: $2,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,117.37 |
| Food and Beverage | $2,673.73 |
| Travel and Lodging | $2,089.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,706.48 | 2022-2025 | |
| Glaxosmithkline, LLC. | $1,379.18 | 2020-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Olympus Corporation of The Americas | $1,278.63 | 2022 | |
| Medtronic, INC. | $768.30 | 2023-2024 | Illumisite |
| Astrazeneca Pharmaceuticals LP | $697.41 | 2020-2025 | Breztri, Fasenra |
| Abiomed | $463.83 | 2023-2025 | Impella |
| Advanced Respiratory, INC | $300.00 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $243.26 | 2021 | |
| Insmed, INC. | $242.80 | 2019-2025 | Arikayce |
| Jazz Pharmaceuticals INC. | $224.99 | 2023 | |
| Noah Medical Corporation | $211.39 | 2024 | Galaxy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.99 | 2025 | Ofev |
| Akebia Therapeutics INC | $124.99 | 2025 | Vafseo |
| Baxter Healthcare | $101.73 | 2019 | |
| Mylan Specialty L.P. | $70.74 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $69.76 | 2021 | |
| Genzyme Corporation | $29.39 | 2025 | |
| Ethicon INC. | $26.55 | 2022 | |
| Galvanize Therapeutics, INC | $25.76 | 2025 | Aliya System |
| Pfizer INC. | $18.00 | 2025 | |
| Grifols USA, LLC | $13.44 | 2023 | Prolastin-C Liquid |
| La Jolla Pharmaceutical Company | $11.49 | 2019 | |
| Veran Medical Technologies, INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Horlander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.